COO

Business profile & competitive position

The Cooper Companies, Inc. (COO) is classified in the Healthcare sector under the Medical – Instruments & Supplies industry. It operates as a global medical device company through two business segments. CooperVision develops, manufactures and markets contact lenses and specialty eyecare products, including silicone hydrogel lenses, orthokeratology and scleral lenses, plus the MiSight 1 day myopia-management lens. CooperSurgical provides more than 600 products and services focused on fertility and women’s health, spanning gynecology, obstetrics, contraception, labor and delivery, cord blood/tissue storage, IVF support, donor gametes, cryopreservation and genomic services. The company’s products are sold in over 130 countries and reach more than fifty million lives annually.

On the numbers, COO’s 13.5% net margin and 6.9% ROE point to a profitable but not especially capital-efficient business. The margin supports the idea that branded medical-device and consumable-lens portfolios carry some pricing power, yet the single-digit ROE suggests reinvestment, goodwill-heavy expansion, or segment mix that keeps returns moderate. With a beta of 0.82, the stock has historically moved less violently than the broader market, consistent with the relatively defensive cash-flow profile of disposable medical supplies. Taken together, the financials describe a resilient but capital-intensive healthcare franchise rather than a high-return, asset-light compounder.

Financial posture

As of the snapshot date, COO carried a market capitalization of $10.6 billion, traded at $54.15, and posted a trailing P/E of 18.5. Those valuation figures sit alongside a 13.5% net margin and a 6.9% ROE, which means investors are paying a mid-teens multiple for a mid-teens margin business that is not currently generating double-digit returns on equity. The stock also traded with a beta of 0.82.

Technically, the stock was severely extended to the downside: the RSI stood at 16.0, well below the 30 threshold commonly associated with oversold conditions, and the price was nearly $15 below the 50-day exponential moving average of $69.38. That gap reflects the acute selling pressure seen around the September 2026 report, not an endorsement either way. The 18.5 P/E can be read as the market pricing in modest growth and some execution risk; the disconnect between a 13.5% margin and a 6.9% ROE underscores how balance-sheet intensity and segment mix may be mutting shareholder returns.

Strategic priorities & outlook

The company’s most recent 10-K highlights four clear operational priorities. First, CooperVision is focused on broader worldwide penetration of recently launched products and on expanding its footprint in both existing and emerging markets. Second, it is increasing investment in distribution and packaging capabilities so that growth does not outrun service levels or quality control. Third, CooperVision is spending to develop the myopia-management market by educating eye care practitioners, patients and families; this reflects MiSight 1 day’s regulatory status as the only contact lens approved by the FDA, Chinese NMPA and Japanese MHLW to slow and correct myopia in age-appropriate children.

Fourth, CooperSurgical intends to keep investing in its business, including through strategic transactions, to expand an integrated solutions model across fertility and women’s health. Operational context matters too: roughly 500 employees work in R&D across both segments, and products reach over 130 countries. In short, management’s roadmap is a mix of geographic expansion, capacity build-out, market education and bolt-on M&A—typical of a diversified medical-device company trying to compound share through category development rather than pure volume.

Macro & geopolitical exposure

Because COO sits in the Medical – Instruments & Supplies industry, its baseline exposures match those of a global medical-device and consumables supplier. Regulatory risk is front-and-center: lenses and fertility devices must win and maintain approvals across multiple jurisdictions, including the FDA, China’s NMPA and Japan’s MHLW. Currency translation is a meaningful factor given sales in more than 130 countries; a stronger U.S. dollar can compress reported revenue and earnings even when local operations are stable.

Trade policy and supply-chain costs also matter. Tariffs or logistical disruptions on raw materials, packaging, silicone hydrogel components, or laboratory supplies can squeeze a medical-supply margin like the 13.5% COO reports. The fertility segment brings additional sensitivity to healthcare spending, reimbursement policy and demographic demand for assisted reproductive services. None of these are company-specific risks; they are inherent exposures for Healthcare / Medical – Instruments & Supplies businesses with global manufacturing and direct-to-practitioner distribution.

Recent developments

The most market-moving headline came on September 12, 2026, when HBSS (via globenewswire.com) reported that The Cooper Companies was scrutinized over U.S. channel inventory reductions, which the article tied to a sharp stock decline. This matches the price action around the September 9, 2026 earnings release, when COO beat the $1.12 estimate by 2.7% with actual EPS of $1.15 yet still fell 14.67% the next day. The channel-inventory narrative suggests the market is less concerned with the quarterly EPS print than with how much product is sitting with U.S. distributors.

On September 11, 2026, two separate law-firm announcements appeared: Levi & Korsinsky notified investors of a pending investigation into Cooper Companies (prnewswire.com), and the Law Offices of Howard G. Smith invited shareholders who lost money to contact the firm about a securities fraud investigation (businesswire.com). A third September 11 headline, “Nike COO Alagirisamy Venkatesh Sells 3,671 Shares” from fool.com, is unrelated to The Cooper Companies and illustrates the kind of ticker-symbol noise that can appear in COO news feeds. Taken together, the recent news flow is dominated by inventory concerns and legal-investigation announcements, not by product launches or M&A.

Earnings behavior & post-earnings drift

COO has an exceptional earnings-beat record over the last eight reported quarters, beating estimates in all eight (100%) with an average positive surprise of 4.2%. The average five-day post-earnings drift across those quarters was 1.54% to the upside. In theory, that combination suggests a company that consistently clears low-to-mid estimates and often sees a modestly positive drift in the days after reports.

The most recent quarter shows why the headline beat rate does not tell the whole story. For the September 9, 2026 quarter, actual EPS of $1.15 beat the $1.11 estimate by 2.7%, yet the stock fell 14.67% the next day and registered a 0% five-day move. The June 4, 2026 quarter was the opposite: a 10% beat (actual $1.21 vs. estimate $1.10) drove an 8.58% next-day gain and an 8.85% five-day advance. The March 5, 2026 quarter was another beat (actual $1.10 vs. estimate $1.03, a 6.8% surprise), but the stock dropped 4.55% the next day and 10.82% over five days. December 4, 2025 brought a 3.6% beat ($1.15 vs. $1.11) and a positive 5.67% next-day move with 6.59% over five days.

The pattern is clear: COO usually beats, but the price reaction depends heavily on guidance, channel dynamics and segment mix. The next scheduled report is December 3, 2026 after the close, with the current consensus EPS estimate at $1.11. Given the recent inventory concerns, the most recent report may be more about forward commentary than the reported number itself.

For a deeper dive into how institutional analysts are interpreting these channel-inventory concerns, earnings consistency, and strategic priorities, readers should review the full institutional verdict on COO to see where the Street currently stands.